Tenax Therapeutics is focused on identifying, developing and commercializing products for the critical care market.In the U.S. alone, more than five million hospitalized patients are treated in an intensive care setting annually according to the Society of Critical Medicine.
The LEVO-CTS trial results will be presented on
Sunday, March 19, 2017, at 8 am EST
during a late-breaking clinical trial session at the
American College of Cardiology
66th Annual Scientific Session in Washington, D.C.
Focus on Critical CareGiven the high mortality, morbidity, and costs associated with the treatment of many intensive care patients, we believe that there is a substantial opportunity to add value for patients, physicians, hospitals, and ultimately shareholders.
Jan 31 2017 Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery Nov 18 2016 Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery Nov 10 2016 Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update